1. |
Siegel R, Naishadham D, Jemal A. Cancer statistics. CA Cancer J Clin, 2012, 62(1):10-29.
|
2. |
Oettle H, Post S, Neuhaus P, et al. Adjuvant chemotherapy with gemcitabin vs. observation in patients undergoing curative-intent resection of pancreatic cancer:A randomized controlled trial. JAMA, 2007, 297(3):267-277.
|
3. |
Ueno H, Kosuge T, Matsuyama Y, et al. A randomized phase Ⅲ trial comparing gemcitabine with surgery-only in patients with resected pancreatic cancer:Japanese study group of adjuvant therapy for pancreatic cancer. Brit J Cancer, 2009, 101(6):908-915.
|
4. |
Kosuge T, Kiuchi T, Mukai K, et al. A multicenter randomized controlled trial to evaluate the effect of adjuvant cisplatin and 5-fluorouracil therapy after curative resection in cases of pancreatic cancer. Jpn J Clin Oncol, 2006, 36(3):159-165.
|
5. |
Bakkevold KE, Arnesjo B, Dahl O, et al. Adjuvant combination chemotherapy (AMF) following radical resection of carcinoma of the pancreas and papilla of vater-results of a controlled, prospective, randomized multicenter study. Eur J Cancer, 1993, 29(5):698-703.
|
6. |
Neoptolemos JP, Dunn JA, Stocken DD, et al. Adjuvant chemoradiotherapy and chemotherapy in resectable pancreatic cancer:a randomized controlled trial. Lancet, 2001, 358(9293):1576-1585.
|
7. |
Neoptolemos JP, Stocken DD, Friess H, et al. A randomized trial of chemoraidotherapy and chemotherapy after resection of pancreatic cancer. N Engl J Med, 2004, 350(12):1200-1210.
|
8. |
Neoptolemos JP, Stocken DD, Smith TC, et al. Adjuvant 5-fluorouracil and folinic acid vs observation for pancreatic cancer:composite data from the ESPAC-1 and-3(vl) trials. Brit J Cancer, 2009, 100(2):246-250.
|
9. |
Pedrazzoli S, DiCarlo V, Dionigi R, et al. Standard versus extended lymphadenectomy associated with pancreaticoduodenectomy in the surgical treatment of adenocarcinoma of the head of the pancreas:a multicenter, prospective, randomized study. Lymphadenectomy Study Group. Ann Surg, 2009, 228(4):508-517.
|
10. |
Yeo CJ, Cameron JL, Lillemoe KD, et al. Pancreaticoduodenectomy with or without distal gastrectomy and extended retroperitoneal lymphadenectomy for periampullary adenocarcima, part 2:randomized control trial evaluating survival, morbidity, and mortality. Ann Surg, 2002, 236(3):355-368.
|
11. |
Farnell MB, Pearson RK, Sarr MG, et al. A prospective randomized trial comparing standard pancreatoduodenectomy with pancreatoduodenectomy with extended lymphadenectomy in resectable pancreatic head adenocarcinoma. Surgery, 2005, 138(4):618-628.
|
12. |
Stocken DD, Buchler MW, Derveins C, et al. Meta-analysis of randomized adjuvant therapy trials for pancreatic cancer. Brit J Cancer, 2005, 92(8):1372-1381.
|
13. |
Burris HA, Moore MJ, Andersen J, et al. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced cancer:a randomized trial. J Clin Oncol, 1997, 15(6):2403-2413.
|
14. |
Higgins JPT, Green S. Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0[updated March 2011]. The Cochrane Collaboration, 2011.
|
15. |
Neuhaus P, Riess H, Post S, et al. CONKO-001:Final results of the randomized, prospective, multicenter phase Ⅲ trial of adjuvant chemotherapy with gemcitabine versus observation in patients with resected pancreatic cancer (PC). J Clin Oncol, 2008, 26(15s):LBA4504.
|
16. |
Warshaw AL, Fernandez-del CC. Pancreatic carcinoma. N Engl J Med, 1992, 326(7):455-465.
|
17. |
Neoptolemos JP, Buchler M, Stocken DD, et al. ESPAC-3(v2):A multicenter, international, open-label, randomized, controlled phase Ⅲ trial of adjuvant 5-fluorouracil/folinic acid (5-FU/FA) versus gemcitabine (GEM) in patients with resected pancreatic ductal adenocarcinoma. J Clin Oncol, 2009, 27(28s):LBA4505.
|
18. |
Takada T, Amano H, Yasuda H, et al. Is postoperative adjuvant chemotherapy useful for gallbladder carcinoma?A phase Ⅲ multicenter prospective randomized controlled trial in patients with resected pancreaticobiliary carcinoma. Cancer, 2002, 95(8):1685-1695.
|
19. |
Klinkenbijl J, Jeekel J, Sahmoud T, et al. Adjuvant radiotherapy and 5-fluorouracil after curative resection of cancer of the pancreas and periampullary region:phase Ⅲ trial of the EORTC Gastrointestinal Tract Cancer Cooperative Group. Ann Surg, 1999, 230(6):776-782.
|
20. |
Regine WF, Winter KW, Abrams R, et al. RTOG 9704 a phase Ⅲ study of adjuvant pre and post chemoradiation (CRT) 5FU vs. gemcitabine (G) for resected pancreatic adenocarcinoma. J Clin Oncol, 2006, 24(18S):LBA4007.
|
21. |
Kalser MH, Ellenberg SS. Pancreatic cancer.Adjuvant combined radiation and chemotherapy following curative resection. Arch Surg, 2006, 120(8):899-903.
|
22. |
Abou-Alfa GK, Letourneau R, Harker G, et al. Randomised phase Ⅲ study of exatecan and gemcitabine compared with gemcitabine alone in untreated advanced pancreatic cancer. J Clin Oncol, 2006, 24(27):4441-4447.
|
23. |
Berlin JD, Catalano P, Thomas JP, et al. Phase Ⅲ study of gemcitabine in combination with fluorouracil vs gemcitabine alone in patients with advanced pancreatic carcinoma:Eastern Cooperative Oncology Group Trial E2297. J Clin Oncol, 2002, 20(15):3270-3275.
|
24. |
Bria E, Milella M, Gelibter A, et al. Gemcitabine-based combination for inoperable pancreatic cancer:have we made real progres? A meta-analysis of 20 phase 3 trials. Cancer, 2007, 110(3):525-533.
|
25. |
Golucci G, Giuliani F, Gebbia V, et al. Gemcitabine alone or with cisplatin for the treatment of patients with locally advanced and/or metastatic pancreatic carcinoma.A prospective, randomised phase Ⅲ study of the Gruppo Oncologico dell'Italia Meridionale. Cancer, 2002, 94(4):902-910.
|
26. |
Sultana A, Smith CT, Cunningham D, et al. Meta-analyses of chemotherapy for locally advanced and metastatic pancreatic cancer:results of secondary end points analyses. Brit J Cancer, 2008, 99(1):6-13.
|
27. |
Burris HA, Moore MJ, Andersen J, et al. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer:a randomized trial. J Clin Oncol, 1997, 15(6):2403-2413.
|
28. |
Suzuki S, Morishita K, Kaji S, et al. Effectiveness of adjuvant chemotherapy using gemcitabine for resected pancreatic cancer. Gan To Kagaku Ryoho, 2011, 38(1):65-68.
|
29. |
Murakami Y, Uemura K, Sudo T, et al. Adjuvant gemcitabine plus S-1 chemotherapy after surgical resection for pancreatic adenocarcinoma. The American Journal of Surgery, 2008, 195(6):757-762.
|